Key Takeaways

• Cardiff Oncology, Inc. is a clinical-stage pharmaceutical company working in precision oncology, and its common stock trades on Nasdaq under the ticker CRDF.
• The company reported financial results for the full year ended December 31, 2025 together with a business update.
• For Q2 2026, Cardiff Oncology reported earnings per share of -$0.14, beating estimates of -$0.16 by 12.50%.
• The latest closing stock price as of September 08, 2026 is 1.10.
• Trefis reports that the stock has lost about 40% since 5/31/2026, naming a dilutive financing event among the key factors.
• Stockholders are being asked to vote at a special meeting on October 22, 2026 on an amendment that would double the company’s share authorization.

What Is Cardiff Oncology (CRDF)?

Cardiff Oncology, Inc. is a clinical-stage pharmaceutical company built around precision oncology: identifying molecular targets in cancer cells, developing targeted therapies aimed at those targets, and testing candidates in clinical trials. The ticker CRDF belongs to Cardiff Oncology, Inc. Common Stock, and Nasdaq publishes historical price data for the shares.

Because the company is clinical-stage, its progress is measured mainly in trial milestones rather than product sales. Two of those milestones appear in its own filings. Data presented on December 10, 2024 provided initial results from the ongoing CRDF-004 Phase 2 randomized clinical trial. Earlier, data presented on September 12, 2022 provided an update of the ongoing TROV-054 phase 1b/2 single arm clinical trial in KRAS-mutated metastatic colorectal cancer.

For an investor, that structure matters more than any single marketing description of the pipeline. A company at this stage funds long research programmes before it has an approved product to sell, so the questions that drive the share price tend to be about trial readouts, cash runway and how new shares are issued to pay for the work.

Financial Performance Overview

Cardiff Oncology reports on a regular cadence. It released results for the full year ended December 31, 2025 alongside a business update, the usual pairing of financial statements with pipeline commentary that clinical-stage companies use.

On a quarterly basis, Cardiff Oncology reported Q2 2026 earnings per share of -$0.14, beating estimates of -$0.16 by 12.50%. A negative figure is normal for a company without meaningful product revenue; the useful signal is the direction of the loss and how it compares with what the market expected, not the headline word “beat”.

Stock price history

Price history for CRDF covers a long stretch. Macrotrends puts the latest closing stock price as of September 08, 2026 at 1.10, with a closing price of 1926.72 on June 08, 2005 at the other end of the series. That range is a reminder to check the basis of any long-run chart before drawing conclusions from it.

More recently, Trefis reports that CRDF stock has lost about 40% since 5/31/2026, listing a dilutive financing event first among the key factors behind the move. Dilution is one of the recurring realities of clinical-stage biotech: research is funded before revenue exists, and equity is a common way to pay for it.

Ownership and insider activity

Insider buying is one data point some investors track. Yahoo Finance reports 2 insider purchases by a director on July 14, 2026, totaling $999,999.68, with both transactions reported by Gary W Pace. Separately, Fintel publishes the institutional ownership structure for CRDF, including current positions held by institutions and funds and the latest changes in position size. Neither source tells you why a position changed, only that it did.

Investor Considerations

Two governance and funding items sit in front of shareholders right now. The first is the special meeting on October 22, 2026, where stockholders are asked to approve an amendment that would double the share authorization. A larger authorized share count gives a company room to issue more stock; whether that room is used, and on what terms, is a separate question that only future filings can answer.

The second is the financing history already reflected in the price. Reading the proxy materials and the annual results directly, rather than a summary of them, is the only way to see the actual terms.

Risk Factors

• Clinical trial outcomes. Results from programmes such as the CRDF-004 Phase 2 randomized clinical trial drive sentiment in both directions, and a setback can reprice the stock quickly.
• Regulatory approval. Oncology candidates face demanding evidence requirements before any approval, and timelines are not in the company’s control.
• Dilution and financing. Trefis attributes part of the decline of about 40% since 5/31/2026 to a dilutive financing event, and the October 22, 2026 vote concerns share authorization.
• Volatility. The gap between a closing price of 1.10 as of September 08, 2026 and the wider price history shows how far this stock can travel.
• Competition. Other companies pursue targeted therapies in the same disease areas, competing for trial sites, investigators and investor attention.

Investment Potential

The case for CRDF rests on execution in the clinic rather than near-term earnings. The milestones worth following are concrete and public: readouts and updates from the CRDF-004 Phase 2 randomized clinical trial, the next set of quarterly results after the Q2 2026 report, the outcome of the special meeting on October 22, 2026, and any subsequent financing disclosed in company filings.

Anyone sizing a position should weigh those catalysts against the funding picture that comes with them. Nothing here is investment advice, and the figures above are point-in-time values that change with trading and with each new filing.

Conclusion

CRDF is Cardiff Oncology, Inc., a clinical-stage company in precision oncology whose shares trade on Nasdaq. The verifiable picture is narrow but clear: full year results through December 31, 2025 delivered with a business update, Q2 2026 earnings per share of -$0.14 against an estimate of -$0.16, a closing price of 1.10 as of September 08, 2026, a decline of about 40% since 5/31/2026 that Trefis links to dilutive financing, insider buying on July 14, 2026, and a shareholder vote on doubling the share authorization set for October 22, 2026. Track those items in the primary filings, and treat anything beyond them as opinion until a filing confirms it.

Frequently Asked Questions

What is Cardiff Oncology (CRDF)?

Cardiff Oncology, Inc. is a clinical-stage pharmaceutical company focused on precision oncology, developing targeted therapies aimed at specific molecular mechanisms in cancer cells. Its common stock trades on Nasdaq under the ticker CRDF.

What were Cardiff Oncology’s most recent reported earnings?

For Q2 2026 the company reported earnings per share of -$0.14, beating estimates of -$0.16 by 12.50%, according to Public. It also reported results for the full year ended December 31, 2025 with a business update.

How has CRDF stock performed recently?

Macrotrends lists a latest closing stock price as of September 08, 2026 of 1.10, and Trefis reports a loss of about 40% since 5/31/2026.

Why does dilution come up so often with CRDF?

Trefis names a dilutive financing event among the key factors behind the recent decline, and stockholders are being asked to vote on October 22, 2026 on an amendment that would double the share authorization.

Has there been insider buying in CRDF?

Yahoo Finance reports 2 insider purchases by a director on July 14, 2026, totaling $999,999.68, both transactions reported by Gary W Pace.

Where can I check CRDF data myself?

Company filings on SEC EDGAR, historical price data on Nasdaq and institutional ownership data on Fintel are the primary places to verify what you read.